Every 8-K that Sensus Healthcare Inc (SRTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SRTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRTS filings page.
Sensus Healthcare reported weak results for the three months ended June 30, 2026, as revenue fell to $2.3 million from $7.3 million a year earlier, a 68.5% decrease. Management attributed the decline mainly to fewer units sold, no sales to a historically large customer, and greater use of Fair Deal Agreements and rentals, which shift revenue recognition over time. Revenue on eight purchased units was deferred to the third quarter due to financing approval timing.
Gross profit declined to $0.8 million with margin of 34.8%, down from 39.7%, reflecting product mix, more international shipments, and upfront costs on Fair Deal placements. Operating expenses fell across general and administrative, selling and marketing, and research and development, yet a $5.7 million tax valuation allowance drove net loss to $8.7 million (or $0.53 per share) versus a $1.0 million loss (or $0.06 per share) last year. Adjusted EBITDA was a negative $3.0 million.
Cash, restricted cash and cash equivalents were $15.2 million as of June 30, 2026, down from $22.1 million at year-end, with no borrowings on the revolving credit line. The company highlighted commercial momentum supported by dedicated CPT codes and noted that CMS has proposed a 26% increase in a hospital-based delivery code, which it views as enhancing the reimbursement outlook for its superficial radiotherapy systems.
Sensus Healthcare, Inc. entered into a new revolving credit facility with City National Bank of Florida, providing up to $15,000,000 in borrowings. The loan bears interest at the Secured Overnight Financing Rate plus 3% per annum and matures on June 5, 2027, unless extended by mutual agreement.
The facility is secured by $2,230,000 in cash collateral and a security interest in all of the company’s assets. The agreement restricts asset sales outside the ordinary course, additional indebtedness, new liens, and removal of the CEO, President, or CFO without the bank’s consent. Sensus must maintain a minimum debt service coverage ratio of 1.50, with customary default provisions that allow the bank to accelerate the loan and exercise remedies against collateral.
Sensus Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on May 29, 2026. Stockholders elected incumbent Class II directors Eric Sachetta and Michael J. Sardano to three-year terms expiring in 2029.
For the director elections, Sachetta received 5,532,247 votes for, 516,567 against, 270,440 abstentions, and 5,000,719 broker non-votes. Sardano received 4,702,852 votes for, 1,346,063 against, 270,339 abstentions, and 5,000,719 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the 2025 executive compensation program, with 4,740,572 votes for, 856,128 against, 722,554 abstentions, and 5,000,719 broker non-votes. In addition, stockholders ratified the appointment of Carr, Riggs & Ingram, LLC as independent registered public accountant for the year ending December 31, 2026, with 10,738,792 votes for, 148,466 against, and 432,715 abstentions.
Sensus Healthcare reported first quarter 2026 revenue of $3.4 million, down from $8.3 million a year earlier, mainly because its historically largest customer did not purchase in the period and more systems were placed under rental and Fair Deal Agreement structures.
Gross margin fell to 29.2% from 52.2% due to product mix, including more international shipments and costs tied to new placements recognized over time. Net loss was $2.6 million, or $0.16 per share, similar to the prior-year quarter, while Adjusted EBITDA declined to negative $4.2 million from negative $2.5 million.
The company ended March 31, 2026 with $18.3 million in cash and cash equivalents and no debt. Management highlighted newly effective dedicated CPT codes for superficial radiotherapy, growing interest from a more diversified customer base, and initiatives to expand higher-margin recurring revenue as it works toward profitability.
Sensus Healthcare reports fourth-quarter and full-year 2025 results, with revenues of $4.9 million for the quarter and $27.5 million for the year, both down sharply from 2024. The decline mainly reflects fewer systems sold and reduced sales to the company’s historically largest customer.
Fourth-quarter gross profit was $1.9 million, or 38.8% of revenues, and the company posted a net loss of $3.2 million, or $0.19 per share. For 2025, gross profit was $11.9 million, or 43.3% of revenue, with a net loss of $7.7 million, or $0.47 per share, compared with net income in 2024.
Management highlighted new dedicated CPT reimbursement codes for treating non-melanoma skin cancer with SRT, a more than 300% per-fraction increase versus the prior delivery code, stronger FDA program utilization, and meaningful international demand. Cash and cash equivalents were $22.1 million as of December 31, 2025, with no debt outstanding.
Sensus Healthcare, Inc. has changed its independent auditor following an acquisition of assets related to Berkowitz Pollack Brant Advisors + CPAs, LLP’s capital markets practice by Carr, Riggs & Ingram, LLC (CRI), effective January 1, 2026. On January 13, 2026, the Audit Committee dismissed Berkowitz Pollack Brant as the company’s independent registered public accounting firm and approved CRI as the new auditor.
Berkowitz Pollack Brant’s audit report on the company’s consolidated financial statements for the year ended December 31, 2024 contained no adverse opinion, no disclaimer of opinion, and was not qualified or modified. The company reports no disagreements with Berkowitz Pollack Brant on accounting, disclosure, or audit matters, and notes a previously disclosed material weakness in information technology general controls that was remediated as of December 31, 2024. The company also states it did not consult with CRI on accounting or audit issues before this appointment.
Sensus Healthcare, Inc. reported that its Board of Directors appointed Larry Biscotti as a Class I director on January 5, 2026, with a term running through the company’s annual meeting in 2028. He will receive the same director compensation as other non-employee board members on a pro-rata annual basis.
The company stated that there are no arrangements or understandings with other persons related to his election and that he has no material interest in any transaction requiring disclosure under SEC rules. The Board determined that Mr. Biscotti qualifies as an independent director under Nasdaq listing standards. The company later issued a press release on January 7, 2026, announcing his election.
Sensus Healthcare appointed Eric Sachetta as a Class II director, filling the vacancy created by the passing of William McCall. His term runs until the 2026 annual meeting. The Board determined he is an independent director under Nasdaq Rule 5605(a)(2), and he has been named to the Audit Committee.
Sachetta is Chief Wealth Services Officer of Sachetta, LLC and a Certified Financial Planner. He will receive the same pro rata compensation as other non‑employee directors. The company reported no arrangements or transactions requiring disclosure under Item 404(a).
Sensus Healthcare, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company furnished this release as Exhibit 99.1 and incorporated it by reference. The press release includes certain non‑GAAP financial measures, along with reconciliations to the most directly comparable GAAP figures. The information provided under this earnings disclosure section, including Exhibit 99.1, is furnished rather than filed, which affects how it is treated under securities law.